logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
EMA ScreenerEMA Screener
SMA ScreenerSMA Screener
WMA ScreenerWMA Screener
OHLC ScreenerOHLC Screener
Fibonacci ScreenerFibonacci Screener
VWAP ScreenerVWAP Screener
Pivot Point ScreenerPivot Point Screener
Overlay ScreenerOverlay Screener
Trend Indicator ScreenerTrend Indicator Screener
Volume Based Indicator ScreenerVolume Based Indicator Screener
Overbought/Sold ScreenerOverbought/Sold Screener
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Medicamen Biotech Ltd

Medicamen Biotech

Small Cap•378 Employees•IPO 1995
Current Price
₹271.55
-13.05 (-4.59%)Updated
NSE :MEDICAMEQ
BSE :531146
Sector :Pharmaceuticals
Today's Range
269
₹271.55
indicator
299.4
52 Week Range
52W Low₹216.95
52W High₹448.80
₹271.55
indicator
Downside25.17%
Upside65.27%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹436.32 Cr
Market Cap
Total market value of company
P/E Ratio
45.16
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
1.45
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹7.84
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
1.86%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
5.61%
ROCE
Return on Capital Employed. >15% is good
Net Margin
6.57%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-12.63%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
5.31%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
-0.02%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
59.30%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.16
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹167.57
Book Value
Net asset value per share
Dividend Yield
0.28%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
40.50%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

3 points
  • •Medicamen Biotech reported a robust quarterly profit growth of 59.30%, indicating improved profitability in the recent period, which is a positive sign for investors looking for earnings momentum.
  • •The company maintains a very healthy balance sheet with a low debt-to-equity ratio of 0.16, suggesting minimal financial risk and strong solvency, which is reassuring for stakeholders.

Weaknesses

7 points
  • •The company's Return on Equity (ROE) is a low 3.39%, signaling inefficient utilization of shareholder capital to generate profits, which is a concern for long-term value creation.
  • •Medicamen Biotech's Return on Capital Employed (ROCE) at 5.61% is significantly lower than its industry peers, suggesting poor operational efficiency and capital allocation.

Opportunities

3 points
  • •Operating within the robust 'Pharmaceuticals' industry, part of the 'Healthcare' sector, the company benefits from increasing global demand and favorable demographic trends.
  • •Given its relatively small market capitalization of 480 Cr, Medicamen Biotech has substantial potential to expand its market share within the growing pharmaceutical sector.

Threats

4 points
  • •Medicamen Biotech faces intense competition from much larger and financially stronger pharmaceutical players, which could hinder its growth and market penetration efforts.
  • •The highly regulated pharmaceutical industry is vulnerable to adverse policy changes, drug pricing controls, or new compliance requirements, potentially impacting profitability.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹351.77+₹80.22+29.54%
R3₹321.37+₹49.82+18.35%
R2₹310.38+₹38.83+14.30%
R1₹290.97+₹19.42+7.15%
PIVOT₹279.988.433.11%
CURRENT₹271.55--
S1₹199.77-₹71.78-26.43%
S2₹230.17-₹41.38-15.24%
S3₹249.58-₹21.97-8.09%
S4₹260.57-₹10.98-4.04%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.81L
(29 May 2026)
+220.5% vs avg
Delivery %
60.9%
(29 May 2026)
+1.6% vs avg
Avg Volume (20D)
0.25L
(30 Apr - 29 May)
20-day average
Avg Delivery %
59.4%
(30 Apr - 29 May)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Venus Remedies Ltd
687.00 %
Highest Dividend Yield
Kopran Ltd
2.26 %

Peer Comparison

Company Name
AHCL
ALBERTDAVD
Albert David Ltd
AMANTA
HALEOSLABS
Haleos Labs Limited
KILITCH
Kilitch Drugs (India) Ltd
KOPRAN
Kopran Ltd
MEDICO
Medico Remedies Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
VALIANTLAB
Valiant Laboratories Ltd
VENUSREM
Venus Remedies Ltd
ZIMLAB
Zim Laboratories Ltd

About

MEDICAMEQ

Medicamen Biotech Ltd

Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is a fully integrated pharmaceutical company with a global reach. Its business model encompasses the entire pharmaceutical value chain, from initial research and development to the final marketing, sales, and distribution of its products. This vertical integration allows for greater control over quality, cost, and time-to-market for its diverse range of pharmaceutical formulations.

Medicamen's product portfolio is extensive and caters to a broad spectrum of therapeutic areas. The company manufactures and sells medications in various forms, including tablets, capsules, oral solutions, and drops. These formulations address critical health needs across multiple therapeutic categories such as oncology (cancer care), cardiology (heart health), central nervous system (CNS) disorders, diabetology (diabetes management), infectious diseases (anti-infectives), antimalarial treatments, vitamins and supplements, other generic medications, and pain management. This diversification minimizes reliance on any single therapeutic area and allows for greater market stability.

The company's operational footprint extends both domestically within India and internationally, signifying a commitment to serving patients globally. While specific details about its international market penetration are not provided, the mention of international distribution indicates a significant presence beyond its home market. This global reach enhances the company's revenue streams and potentially mitigates risks associated with dependence on a single geographic region.

In summary, Medicamen Biotech Limited is a well-established pharmaceutical company with a vertically integrated business model. Its diverse product portfolio, spanning numerous therapeutic areas and dosage forms, coupled with its domestic and international distribution network, positions it as a significant player in the pharmaceutical industry. The company's long history and comprehensive approach to pharmaceutical production and distribution suggest a robust and sustainable business model.

COMPANY FACTS - MEDICAMEQ

Registered Address

1506, Chiranjiv Tower, 43, Nehru Place

New Delhi

DELHI

IN

Tel: 911147589500

Website:https://medicamen.com/

Investor Relations:http://www.medicamen.com/investors.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 378

IPO Date: 27/07/1995

MANAGEMENT - MEDICAMEQ

Mr. Rahul Bishnoi

Non-Executive Chairman of the Board

Mr. Rajesh Madan

Chief Executive Officer

Mr. Chandan Kumar

Chief Financial Officer

Ms. Parul Choudhary

Compliance Officer, Company Secretary

Mr. Ashwani Sharma

Whole Time Director

Mr. Sanjay Bansal

Non-Executive Director

Dr. Vimal Shrawat

Non-Executive Director

Mr. Suresh Singh

Non-Executive Director

Mr. Sham Goel

Additional Independent Director

Mr. Shaival Saurabh

Additional Independent Director

Dr. Ravi Bansal

Non-Executive Independent Director

Ms. Sangeeta Bishnoi

Non-Executive Independent Director

Investor Questions Answered

Medicamen Biotech Ltd (MEDICAMEQ) Stock FAQs

Get answers to the most common questions about Medicamen Biotech Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Medicamen Biotech Ltd (MEDICAMEQ) is ₹271.55. Today, the stock has declined by ₹13.05 (4.59%), trading in a range of ₹269 to ₹299.4. The stock opened at ₹286.25 with a trading volume of 80,954 shares.
Medicamen Biotech Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹436.32 crores, P/E ratio of 45.16, ROE of 1.86%, and ROCE of 5.61%. The dividend yield stands at 0.28%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Medicamen Biotech Ltd (MEDICAMEQ) is ₹448.8, while the 52-week low is ₹216.95. Currently trading at ₹271.55, the stock is 23.5% away from its 52-week low and 39.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Medicamen Biotech Ltd stock at ₹271.55 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.16 and P/B ratio of N/A. Today's performance shows a loss of 4.59%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Medicamen Biotech Ltd offers a dividend yield of 0.28%, which means for every ₹100 invested at the current price of ₹271.55, you can expect to receive approximately ₹0.28 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Medicamen Biotech Ltd's key financial metrics include: P/E Ratio: 45.16, P/B Ratio: N/A, ROE: 1.86%, ROCE: 5.61%, Dividend Yield: 0.28%, EPS: ₹7.84, Book Value: ₹167.57, Debt-to-Equity: 0.16, and Current Ratio: N/A. The company's market cap stands at ₹436.32 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Medicamen Biotech Ltd stock opened at ₹286.25 and is currently trading at ₹271.55, showing a decline of ₹13.05 (4.59%). The intraday high is ₹299.4 and low is ₹269. The trading volume stands at 80,954 shares, indicating moderate market participation today.
Medicamen Biotech Ltd has a Price-to-Earnings (P/E) ratio of 45.16, which means investors are willing to pay ₹45.16 for every ₹1 of earnings. With an EPS of ₹7.84, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Medicamen Biotech Ltd has a market capitalization of ₹436.32 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹271.55) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Medicamen Biotech Ltd has a book value of ₹167.57 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹271.55, which is 62.1% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Medicamen Biotech Ltd has a Return on Equity (ROE) of 1.86% and Return on Capital Employed (ROCE) of 5.61%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Medicamen Biotech Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Medicamen Biotech Ltd has a debt-to-equity ratio of 0.16, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Medicamen Biotech Ltd has an Earnings Per Share (EPS) of ₹7.84, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹271.55 and P/E ratio of 45.16, investors are paying 45.16 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Medicamen Biotech Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Medicamen Biotech Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Medicamen Biotech Ltd stock, consider: 1) Fundamental Analysis - Review P/E (45.16), ROE (1.86%), debt-to-equity (0.16), and growth rates. 2) Technical Analysis - Check 52-week range (₹216.95 - ₹448.80), moving averages, and chart patterns. 3) Valuation - Compare current price (₹271.55) with book value (₹167.57) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Medicamen Biotech Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹271.55 is 2616x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Medicamen Biotech Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹216.95 - ₹448.80). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.16 indicates leverage. 4) Liquidity Risk - Based on trading volume of 80,954 shares. 5) Valuation Risk - P/E of 45.16 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Medicamen Biotech Ltd operates in the industry with key metrics: P/E ratio of 45.16, ROE of 1.86%, market cap of ₹436.32 crores, and dividend yield of 0.28%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.16), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Medicamen Biotech Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹271.55, with a 52-week range of ₹216.95 to ₹448.80. Based on fundamentals like P/E (45.16), ROE (1.86%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Medicamen Biotech Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹271.55. 2) Fundamental Deterioration - Declining ROE (currently 1.86%), increasing debt (D/E: 0.16), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Medicamen Biotech Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.28%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.

Related

Peers, sector trends, screeners and strategy playbooks contextual to this stock.